We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rapid Solutions for Point-of-Care Diagnostics Provided Worldwide

By LabMedica International staff writers
Posted on 15 Jun 2009
A range of rapid diagnostic tests used for the detection of infectious diseases offers fast and cost-effective clinical solutions for point-of-care diagnostic testing.

The QuickVue range includes qualitative detection of influenza type A and type B antigens, a dipstick immunoassay for acute respiratory syncytial virus (RSV) infections, and a one-step human chorionic gonadotropin (hCG) test, as well as quick and simple tests for Helicobacter pylori, Chlamydia, and Streptococcus group A infections.

BioMerieux (Marcy l'Etoile, France) is now supplying the QuickVue range of rapid diagnostic tests worldwide, as part of a global alliance with Quidel Corp. More...
(San Diego, CA, USA) for the development and distribution of rapid clinical diagnostic solutions. Many new tests are in the development pipeline.

The long-term global alliance between Quidel and bioMérieux was originally formed in 2008. The two companies planned to codevelop new rapid tests using Quidel's rapid test development capability and bioMérieux's expertise in immunochemistry and wide-ranging library of biologics, including antibodies and antigens.

BioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination. Its products are used for diagnosing infectious diseases, for providing results for cancer screening and monitoring, and cardiovascular emergencies.

Quidel develops rapid diagnostic tests that allow for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care, and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit.

Related Links:

bioMerieux
Quidel



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.